If amyloid accumulates 15+ years before clinical decline and triggers tau and neurodegeneration, then anti-amyloid drugs must be deployed in the preclinical window to show large benefits. Modest effects in symptomatic patients reflect late intervention, not a failed target.
— This reframes drug-approval, screening, and trial design toward prevention and early detection rather than late-stage rescue.
BeauHD
2025.10.16
50% relevant
While conducted in symptomatic mice, the finding that facilitating endogenous clearance via BBB repair restores cognition supports the broader prevention/early‑intervention frame that reducing amyloid burden can change disease course.
BeauHD
2025.10.16
45% relevant
Focused ultrasound’s ability to open the blood‑brain barrier offers a delivery route for early anti‑amyloid or other disease‑modifying drugs, which dovetails with the argument that Alzheimer’s therapies must be deployed preclinically for meaningful benefit.
Scott Alexander
2025.08.14
100% relevant
The post’s A→T→N model and the observation that Aduhelm-like drugs only modestly slow progression when given after symptoms emerge.
← Back to All Ideas